Jolanda Howe Sells 2,594 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,594 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total transaction of $264,458.30. Following the sale, the senior vice president directly owned 5,835 shares in the company, valued at $594,878.25. The trade was a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $107.13 on Friday. The company has a market capitalization of $6.53 billion, a P/E ratio of -7.87 and a beta of 0.50. The company has a fifty day moving average price of $98.70 and a 200-day moving average price of $92.22. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. Mirum Pharmaceuticals, Inc. has a 52-week low of $47.89 and a 52-week high of $114.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.30) EPS. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on MIRM. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, June 8th. Citizens Jmp lifted their price objective on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research note on Monday, June 15th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Royal Bank Of Canada increased their target price on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley raised their price target on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $139.80.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. CIBC Private Wealth Group LLC bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $32,000. Quantbot Technologies LP bought a new stake in Mirum Pharmaceuticals in the third quarter worth approximately $33,000. Finally, Comerica Bank lifted its stake in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.